<DOC>
	<DOC>NCT00654381</DOC>
	<brief_summary>The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (BI 1356) (5 mg or 10 mg / once daily) compared to placebo given for 12 weeks and voglibose for 26 weeks as mono therapy in patients with type 2 diabetes mellitus with insufficient glycaemic control. Furthermore, long-term safety is evaluated with an extension treatment to 52 weeks.</brief_summary>
	<brief_title>Japanese P III vs Voglibose and Placebo</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Inclusion criteria: 1. Japanese patients with a diagnosis of type 2 diabetes mellitus. Antidiabetic therapy has to be stable for at least 10 weeks before Visit 1. 2. Glycosylated haemoglobin A1 (HbA1c) 7.0 10.0% at Visit 3 (beginning of the 2week placebo runin phase) 3. Age: &gt;= 20 and &lt;= 80 4. Body Mass Index (BMI) &lt;= 40 kg/m2 Exclusion criteria: 1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months before Visit 1 2. Impaired hepatic function 3. History of severe allergy/hypersensitivity 4. Treatment with antidiabetic, anti obesity drugs, etc 3 months before Visit 1 5. Fasting blood glucose &gt;240 mg/dl (=13.3 mmol/L) at Visits 2 or 3</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>